While early observational studies investigating the relation of the APOE polymorphism and the risk of fatty liver disease, or NAFLD in particular, hardly find any significance [35-37], Sazci et al. reported an apparent accumulation of APOE epsilon 3 homozygotes in NASH patients in 2008 [38]. The gene discussed is APOE; the disease is metabolic dysfunction-associated steatohepatitis.